联合吸入治疗慢性阻塞性肺病稳定期患者的疗效观察

The curative effects of ipratropium bromide inhalation aerosol combined with salmeterol fluticasone propionate inhalation powder on chronic obstructive pulmonary disease patients in stable phase

目的观察联合吸入异丙托溴铵气雾剂和沙美特罗/替卡松粉吸入剂对慢性阻塞性肺病(COPD)稳定期患者的疗效。方法采用随机、盲法、平行对照研究,将80例COPD患者随机分为观察组和对照组,疗程24周。观察组给予异丙托溴铵气雾剂和沙美特罗/替卡松粉吸入剂治疗,对照组给予异丙托溴铵气雾剂治疗。分别对两组患者治疗前后的临床症状积分(SGRQ)、肺功能的检测情况进行比较。结果 SGRQ积分,两组治疗后均较治疗前有明显下降,而观察组下降比对照组更显著(P<0.05);第一秒用力呼气容积(FEV1)/用力肺活量(FVC)、第1秒用力呼吸气量占预计值的百分比(FEV1%)指标治疗后两组具有不同程度的改善,观察组肺功能指标优于对照组(P<0.05)。结论联合吸入异丙托溴铵气雾剂和沙美特罗/替卡松粉吸入剂治疗COPD稳定期患者不仅能够改善肺功能,而且能提高患者运动耐力和改善生活质量,具有较好的治疗效果。

Objective To observe the effect of ipratropium bromide inhalation aerosol combined with salmeterol fluticasone propionate inhalation powder on chronic obstructive pulmonary disease（COPD） patients in stable phase.Methods A randomized,blinding,parallel control study was used in this study.80 patients with COPD were randomly divided into two groups and treated for 24 weeks.Observation group was treated with ipratropium bromide aerosol and fluticasone salmeterol powder inhalation therapy,while control group was only received ipratropium bromide aerosol.The effects of two therapeutic plans were evaluated by the clinical symptom score（SGRQ） and pulmonary function testing.Results After treatment,two groups SGRQ scores were lower than before,and the score of observation group was significantly lower than that of control group（P0.05）.FEV1/FVC,the percentage of Forced expiratory volume in 1 second（FEV1） percentage of predicted value（FEV1%） of two groups were shown varying degrees of improvement after treatment,and these data of observation group are better than that of control group（P0.05）.Conclusion Treatment of stable COPD patients by using inhalation aerosol ipratropium bromide and salmeterol fluticasone propionate inhalation powder can not only make their lung function better,but also can improve their exercise tolerance and quality of life.